Poniard Pharma (PARD) option volume and prices elevated into data
Poniard (Nasdaq: PARD) closed at $7.09. PARD is a biopharmaceutical company focused on development of oncology products. SPEAR Phase three study in small cell lung cancer (SCLC) on PARD's Picoplatin is expected by year end 2009. The study was designed to evaluate picoplatin vs. best supportive care for the treatment of platinum resistant/refractory SCLC. PARD November 7.5 straddle $3.15, December is at $5.95. PARD November option implied volatility is at 272, December is at 296, March is at 198, according to Track Data. Paul Foster
You May Also Be Interested In
- Celldex (CLDX) volatility up into conference call to announce EMERGE results
- Stocks with implied volatility below IV index mean; HLF ARNA
- Stocks with implied volatility movement; NOK GLW
Create E-mail Alert Related Categories
FDA, OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
